Fallopian Tube Cancer-Pipeline Review, H1 2015

Fallopian Tube Cancer-Pipeline Review, H1 2015

  • Products Id :- GMDHC6248IDB
  • |
  • Pages: 432
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Fallopian Tube Cancer-Pipeline Review, H1 2015


Global Markets Direct's, 'Fallopian Tube Cancer-Pipeline Review, H1 2015', provides an overview of the Fallopian Tube Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Fallopian Tube Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Fallopian Tube Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 9

Global Markets Direct Report Coverage 9

Fallopian Tube Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Fallopian Tube Cancer-Overview 11

Pipeline Products for Fallopian Tube Cancer-Comparative Analysis 12

Fallopian Tube Cancer-Therapeutics under Development by Companies 13

Fallopian Tube Cancer-Therapeutics under Investigation by Universities/Institutes 18

Fallopian Tube Cancer-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Fallopian Tube Cancer-Products under Development by Companies 22

Fallopian Tube Cancer-Products under Investigation by Universities/Institutes 27

Fallopian Tube Cancer-Companies Involved in Therapeutics Development 28

AbbVie Inc. 28

Acceleron Pharma, Inc. 29

Adaptimmune Limited 30

Amgen Inc. 31

Array BioPharma Inc. 32

Astex Pharmaceuticals, Inc. 33

AstraZeneca PLC 34

Bayer AG 35

BioMarin Pharmaceutical Inc. 36

Bionomics Limited 37

Boehringer Ingelheim GmbH 38

Celldex Therapeutics, Inc. 39

Celsion Corporation 40

Cerulean Pharma, Inc. 41

Clovis Oncology, Inc. 42

Corcept Therapeutics Incorporated 43

CTI BioPharma Corp. 44

Curis, Inc. 45

Eli Lilly and Company 46

Exelixis, Inc. 47

F. Hoffmann-La Roche Ltd. 48

Galena Biopharma, Inc. 49

Genentech, Inc. 50

GlaxoSmithKline plc 51

Glycotope GmbH 52

Gradalis Inc. 53

ImmunoGen, Inc. 54

Immunotope, Inc. 55

Immunovaccine, Inc. 56

Johnson & Johnson 57

Karyopharm Therapeutics, Inc. 58

Lee's Pharmaceutical Holdings Limited 59

MabVax Therapeutics Holdings, Inc. 60

MedImmune, LLC 61

Merck & Co., Inc. 62

Merrimack Pharmaceuticals, Inc. 63

Millennium Pharmaceuticals, Inc. 64

NeoStem, Inc. 65

Novartis AG 66

Oasmia Pharmaceutical AB 67

OBI Pharma, Inc. 68

Oncolytics Biotech Inc. 69

OncoMed Pharmaceuticals, Inc. 70

Onxeo SA 71

Oxford BioMedica plc 72

OXiGENE, Inc. 73

Pharma Mar, S.A. 74

Pharmacyclics, Inc. 75

PsiOxus Therapeutics, Ltd. 76

Recepta Biopharma S.A. 77

Sanofi Pasteur SA 78

Sotio a.s. 79

Synta Pharmaceuticals Corp. 80

TapImmune Inc. 81

Tesaro, Inc. 82

TetraLogic Pharmaceuticals 83

TRACON Pharmaceuticals, Inc. 84

VentiRx Pharmaceuticals, Inc. 85

Fallopian Tube Cancer-Therapeutics Assessment 86

Assessment by Monotherapy Products 86

Assessment by Target 87

Assessment by Mechanism of Action 91

Assessment by Route of Administration 94

Assessment by Molecule Type 96

Drug Profiles 98

abexinostat hydrochloride-Drug Profile 98

abiraterone acetate-Drug Profile 100

ABT-767-Drug Profile 103

alisertib-Drug Profile 104

anetumab ravtansine-Drug Profile 108

AZD-1775-Drug Profile 110

AZD-2014-Drug Profile 112

AZD-5363-Drug Profile 114

belinostat-Drug Profile 116

bevacizumab-Drug Profile 119

binimetinib-Drug Profile 124

birinapant-Drug Profile 128

BNC-105P-Drug Profile 131

cabozantinib s-malate-Drug Profile 133

Cancer Stem Cell Therapy-Drug Profile 136

CDX-1401-Drug Profile 137

Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology-Drug Profile 139

Cell Therapy to Target WT1 for Cancer-Drug Profile 141

CRLX-101-Drug Profile 142

CUDC-427-Drug Profile 144

dalantercept-Drug Profile 145

DCVAC/OvCa-Drug Profile 147

demcizumab-Drug Profile 148

Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer-Drug Profile 152

DMUC-4064A-Drug Profile 153

DPX-Survivac-Drug Profile 154

EGEN-001-Drug Profile 157

elesclomol-Drug Profile 159

enadenotucirev-Drug Profile 161

erismodegib-Drug Profile 163

fosbretabulin tromethamine-Drug Profile 166

GALE-301-Drug Profile 170

ganetespib-Drug Profile 172

gimatecan-Drug Profile 176

guadecitabine-Drug Profile 178

IMGN-853-Drug Profile 181

IMT-1012-Drug Profile 182

ipafricept-Drug Profile 183

LCL-161-Drug Profile 185

lifastuzumab vedotin-Drug Profile 187

LY-2606368-Drug Profile 189

mifepristone-Drug Profile 190

MK-2206-Drug Profile 193

motolimod-Drug Profile 196

nintedanib-Drug Profile 198

niraparib-Drug Profile 202

NSC-748933-Drug Profile 204

OBI-822/821-Drug Profile 205

olaratumab-Drug Profile 207

paclitaxel-Drug Profile 209

paclitaxel poliglumex-Drug Profile 211

PankoMab-GEX-Drug Profile 215

pazopanib hydrochloride-Drug Profile 216

pelareorep-Drug Profile 221

ralimetinib mesylate-Drug Profile 226

ramucirumab-Drug Profile 227

RebmAb-100-Drug Profile 232

regorafenib-Drug Profile 234

rucaparib phosphate-Drug Profile 237

selinexor-Drug Profile 240

seribantumab-Drug Profile 244

SG-2000-Drug Profile 247

talazoparib-Drug Profile 249

TPIV-200-Drug Profile 252

trabectedin-Drug Profile 254

TRC-105-Drug Profile 258

trebananib-Drug Profile 260

TroVax-Drug Profile 263

Vaccine for cancer-Drug Profile 266

Vaccine for Oncology-Drug Profile 268

varlilumab-Drug Profile 269

vCP-2292-Drug Profile 271

X-82-Drug Profile 273

Fallopian Tube Cancer-Recent Pipeline Updates 275

Fallopian Tube Cancer-Dormant Projects 417

Fallopian Tube Cancer-Discontinued Products 419

Fallopian Tube Cancer-Product Development Milestones 420

Featured News & Press Releases 420

Appendix 426

Methodology 426

Coverage 426

Secondary Research 426

Primary Research 426

Expert Panel Validation 426

Contact Us 426

Disclaimer 427

List of Tables

Number of Products under Development for Fallopian Tube Cancer, H1 2015 16

Number of Products under Development for Fallopian Tube Cancer-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 19

Number of Products under Development by Companies, H1 2015 (Contd..1) 20

Number of Products under Development by Companies, H1 2015 (Contd..2) 21

Number of Products under Development by Companies, H1 2015 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Development by Companies, H1 2015 (Contd..4) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Fallopian Tube Cancer-Pipeline by AbbVie Inc., H1 2015 33

Fallopian Tube Cancer-Pipeline by Acceleron Pharma, Inc., H1 2015 34

Fallopian Tube Cancer-Pipeline by Adaptimmune Limited, H1 2015 35

Fallopian Tube Cancer-Pipeline by Amgen Inc., H1 2015 36

Fallopian Tube Cancer-Pipeline by Array BioPharma Inc., H1 2015 37

Fallopian Tube Cancer-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 38

Fallopian Tube Cancer-Pipeline by AstraZeneca PLC, H1 2015 39

Fallopian Tube Cancer-Pipeline by Bayer AG, H1 2015 40

Fallopian Tube Cancer-Pipeline by BioMarin Pharmaceutical Inc., H1 2015 41

Fallopian Tube Cancer-Pipeline by Bionomics Limited, H1 2015 42

Fallopian Tube Cancer-Pipeline by Boehringer Ingelheim GmbH, H1 2015 43

Fallopian Tube Cancer-Pipeline by Celldex Therapeutics, Inc., H1 2015 44

Fallopian Tube Cancer-Pipeline by Celsion Corporation, H1 2015 45

Fallopian Tube Cancer-Pipeline by Cerulean Pharma, Inc., H1 2015 46

Fallopian Tube Cancer-Pipeline by Clovis Oncology, Inc., H1 2015 47

Fallopian Tube Cancer-Pipeline by Corcept Therapeutics Incorporated, H1 2015 48

Fallopian Tube Cancer-Pipeline by CTI BioPharma Corp., H1 2015 49

Fallopian Tube Cancer-Pipeline by Curis, Inc., H1 2015 50

Fallopian Tube Cancer-Pipeline by Eli Lilly and Company, H1 2015 51

Fallopian Tube Cancer-Pipeline by Exelixis, Inc., H1 2015 52

Fallopian Tube Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 53

Fallopian Tube Cancer-Pipeline by Galena Biopharma, Inc., H1 2015 54

Fallopian Tube Cancer-Pipeline by Genentech, Inc., H1 2015 55

Fallopian Tube Cancer-Pipeline by GlaxoSmithKline plc, H1 2015 56

Fallopian Tube Cancer-Pipeline by Glycotope GmbH, H1 2015 57

Fallopian Tube Cancer-Pipeline by Gradalis Inc., H1 2015 58

Fallopian Tube Cancer-Pipeline by ImmunoGen, Inc., H1 2015 59

Fallopian Tube Cancer-Pipeline by Immunotope, Inc., H1 2015 60

Fallopian Tube Cancer-Pipeline by Immunovaccine, Inc., H1 2015 61

Fallopian Tube Cancer-Pipeline by Johnson & Johnson, H1 2015 62

Fallopian Tube Cancer-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 63

Fallopian Tube Cancer-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 64

Fallopian Tube Cancer-Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 65

Fallopian Tube Cancer-Pipeline by MedImmune, LLC, H1 2015 66

Fallopian Tube Cancer-Pipeline by Merck & Co., Inc., H1 2015 67

Fallopian Tube Cancer-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 68

Fallopian Tube Cancer-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 69

Fallopian Tube Cancer-Pipeline by NeoStem, Inc., H1 2015 70

Fallopian Tube Cancer-Pipeline by Novartis AG, H1 2015 71

Fallopian Tube Cancer-Pipeline by Oasmia Pharmaceutical AB, H1 2015 72

Fallopian Tube Cancer-Pipeline by OBI Pharma, Inc., H1 2015 73

Fallopian Tube Cancer-Pipeline by Oncolytics Biotech Inc., H1 2015 74

Fallopian Tube Cancer-Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 75

Fallopian Tube Cancer-Pipeline by Onxeo SA, H1 2015 76

Fallopian Tube Cancer-Pipeline by Oxford BioMedica plc, H1 2015 77

Fallopian Tube Cancer-Pipeline by OXiGENE, Inc., H1 2015 78

Fallopian Tube Cancer-Pipeline by Pharma Mar, S.A., H1 2015 79

Fallopian Tube Cancer-Pipeline by Pharmacyclics, Inc., H1 2015 80

Fallopian Tube Cancer-Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 81

Fallopian Tube Cancer-Pipeline by Recepta Biopharma S.A., H1 2015 82

Fallopian Tube Cancer-Pipeline by Sanofi Pasteur SA, H1 2015 83

Fallopian Tube Cancer-Pipeline by Sotio a.s., H1 2015 84

Fallopian Tube Cancer-Pipeline by Synta Pharmaceuticals Corp., H1 2015 85

Fallopian Tube Cancer-Pipeline by TapImmune Inc., H1 2015 86

Fallopian Tube Cancer-Pipeline by Tesaro, Inc., H1 2015 87

Fallopian Tube Cancer-Pipeline by TetraLogic Pharmaceuticals, H1 2015 88

Fallopian Tube Cancer-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 89

Fallopian Tube Cancer-Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 90

Assessment by Monotherapy Products, H1 2015 91

Number of Products by Stage and Target, H1 2015 93

Number of Products by Stage and Mechanism of Action, H1 2015 97

Number of Products by Stage and Route of Administration, H1 2015 100

Number of Products by Stage and Molecule Type, H1 2015 102

Fallopian Tube Cancer Therapeutics-Recent Pipeline Updates, H1 2015 280

Fallopian Tube Cancer-Dormant Projects, H1 2015 422

Fallopian Tube Cancer-Dormant Projects (Contd..1), H1 2015 423

Fallopian Tube Cancer-Discontinued Products, H1 2015 424

List of Figures

Number of Products under Development for Fallopian Tube Cancer, H1 2015 16

Number of Products under Development for Fallopian Tube Cancer-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Assessment by Monotherapy Products, H1 2015 91

Number of Products by Top 10 Targets, H1 2015 92

Number of Products by Stage and Top 10 Targets, H1 2015 92

Number of Products by Top 10 Mechanism of Actions, H1 2015 96

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 96

Number of Products by Top 10 Routes of Administration, H1 2015 99

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 100

Number of Products by Top 10 Molecule Types, H1 2015 101

Number of Products by Stage and Top 10 Molecule Types, H1 2015 102

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

AbbVie Inc.

Acceleron Pharma, Inc.

Adaptimmune Limited

Amgen Inc.

Array BioPharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca PLC

Bayer AG

BioMarin Pharmaceutical Inc.

Bionomics Limited

Boehringer Ingelheim GmbH

Celldex Therapeutics, Inc.

Celsion Corporation

Cerulean Pharma, Inc.

Clovis Oncology, Inc.

Corcept Therapeutics Incorporated

CTI BioPharma Corp.

Curis, Inc.

Eli Lilly and Company

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Galena Biopharma, Inc.

Genentech, Inc.

GlaxoSmithKline plc

Glycotope GmbH

Gradalis Inc.

ImmunoGen, Inc.

Immunotope, Inc.

Immunovaccine, Inc.

Johnson & Johnson

Karyopharm Therapeutics, Inc.

Lee's Pharmaceutical Holdings Limited

MabVax Therapeutics Holdings, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

Millennium Pharmaceuticals, Inc.

NeoStem, Inc.

Novartis AG

Oasmia Pharmaceutical AB

OBI Pharma, Inc.

Oncolytics Biotech Inc.

OncoMed Pharmaceuticals, Inc.

Onxeo SA

Oxford BioMedica plc


Pharma Mar, S.A.

Pharmacyclics, Inc.

PsiOxus Therapeutics, Ltd.

Recepta Biopharma S.A.

Sanofi Pasteur SA

Sotio a.s.

Synta Pharmaceuticals Corp.

TapImmune Inc.

Tesaro, Inc.

TetraLogic Pharmaceuticals

TRACON Pharmaceuticals, Inc.

VentiRx Pharmaceuticals, Inc.

Fallopian Tube Cancer Therapeutic Products under Development, Key Players in Fallopian Tube Cancer Therapeutics, Fallopian Tube Cancer Pipeline Overview, Fallopian Tube Cancer Pipeline, Fallopian Tube Cancer Pipeline Assessment

select a license

Single User License
USD 2000 INR 135980
Site License
USD 4000 INR 271960
Corporate User License
USD 6000 INR 407940



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com